Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group

2016 ◽  
Vol 70 (4) ◽  
pp. 320-326 ◽  
Author(s):  
Syed Salahuddin Ahmed ◽  
Aye Aye Thike ◽  
Kathryn Zhang ◽  
Jeffrey Chun Tatt Lim ◽  
Puay Hoon Tan
Keyword(s):  
Ductal Carcinoma ◽  
Histological Grade ◽  
Tumour Size ◽  
Hormonal Treatment ◽  
Tissue Microarrays ◽  
Prognostic Indicator ◽  
Early Recurrence ◽  
Clinicopathological Parameters ◽  
Lymph Node Status ◽  
Breast Cancers

AimsThe presence of oestrogen and progesterone receptors (ER, PR) in breast carcinoma is an important prognostic indicator as well as a predictor of likely response to hormonal treatment. Current ambiguity surrounds ER-negative (–)/PR-positive (+) breast cancer (BC) as to whether this phenotype exists as a distinct entity. The independent predictive value of PR for treatment considerations is also in question, as some investigators believe ER status to be the single most important therapeutic predictive factor in BC. We undertook this study to determine the existence of ER(–)/PR(+) BC and the prognostic effect, if any, of this phenotype.MethodsWe investigated 267 archival documented ER(–)/PR(+) BCs diagnosed between January 1994 and July 2009. Histological slides were retrieved and reviewed. Tissue microarrays were constructed by selecting two 1 mm cores of tumour per case. Repeat immunohistochemistry was performed for confirmation of the ER(–)/PR(+) status. Clinicopathological parameters including age, ethnicity, tumour size, histological grade, histological subtype, associated ductal carcinoma in situ, lymphovascular invasion and lymph node status were evaluated.ResultsOn repeat immunohistochemistry, 92 tumours were confirmed as ER(–)/PR(+) BCs. This phenotype accounted for 1.1% of all BC phenotypes and exhibited different clinicopathological features and survival outcome when compared with other phenotypes. ER(–)/PR(+) tumours showed a trend for an early recurrence and poorer overall survival as compared with the patients with ER(+)/PR(+) tumours and similar to ER(–)/PR(–) tumours.ConclusionsOur findings suggest that ER(–)/PR(+) BCs exist, although rare, with distinct pathological and clinical characteristics from patients with ER(+)/PR(+) BCs.

scholarly journals Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer

2021 ◽  
Author(s):  
E. Amiri Souri ◽  
A. Chenoweth ◽  
A. Cheung ◽  
S. N. Karagiannis ◽  
S. Tsoka
Keyword(s):  
Breast Cancer ◽  
Machine Learning ◽  
Clinical Decision Making ◽  
Histological Grade ◽  
Tumour Size ◽  
Clinical Decision ◽  
Gene Signature ◽  
Risk Classification ◽  
Breast Cancers ◽  
Grade 3

Abstract Background Prognostic stratification of breast cancers remains a challenge to improve clinical decision making. We employ machine learning on breast cancer transcriptomics from multiple studies to link the expression of specific genes to histological grade and classify tumours into a more or less aggressive prognostic type. Materials and methods Microarray data of 5031 untreated breast tumours spanning 33 published datasets and corresponding clinical data were integrated. A machine learning model based on gradient boosted trees was trained on histological grade-1 and grade-3 samples. The resulting predictive model (Cancer Grade Model, CGM) was applied on samples of grade-2 and unknown-grade (3029) for prognostic risk classification. Results A 70-gene signature for assessing clinical risk was identified and was shown to be 90% accurate when tested on known histological-grade samples. The predictive framework was validated through survival analysis and showed robust prognostic performance. CGM was cross-referenced with existing genomic tests and demonstrated the competitive predictive power of tumour risk. Conclusions CGM is able to classify tumours into better-defined prognostic categories without employing information on tumour size, stage, or subgroups. The model offers means to improve prognosis and support the clinical decision and precision treatments, thereby potentially contributing to preventing underdiagnosis of high-risk tumours and minimising over-treatment of low-risk disease.

scholarly journals Expression of CD4, CD8 Biomarkers in Invasive Carcinoma of Breast with Clinicopathological Correlation

2021 ◽  
pp. 65-73
Author(s):  
C. Divyapriya ◽  
Aarthi Kannan ◽  
Vijayashree Raghavan
Keyword(s):  
Breast Cancer ◽  
T Lymphocytes ◽  
Invasive Breast Cancer ◽  
Triple Negative ◽  
Invasive Carcinoma ◽  
Tumour Size ◽  
Breast Cancer Subtype ◽  
Lymph Node Status ◽  
Breast Cancers ◽  
Cd8 T Lymphocytes

Introduction: Tumor infiltrating lymphocytes (TILs) are widely considered a key sign of the immune interaction between host and tumor, and potentially prognostic biomarkers of good or bad outcome in various cancers, including invasive breast cancer (IBC). Aim and Objectives: To correlate the expression of CD4, CD8 T-lymphocytes in invasive carcinoma breast with established markers of prognosis like tumour size, grade, lymph node status and molecular subtypes mainly ER, PR, Her 2Neu, Ki67 status, mainly the triple negative breast cancers(TNBC). Methodology: 58 Invasive breast carcinoma proven tissue blocks were subjected to immunohistochemistry and morphometric analysis for positive CD4, CD8 T-lymphocytes were done. Results:  Triple negative breast cancer subtype shows high TILs than other pathologic subtypes. Tumor interface CD8+ cells very well correlated with the pathological higher nodal stage. Majority CD4, CD8 positive cells were populated more towards the stromal and interface of the tumor microenvironment rather thatintratumoral. Conclusion: CD4+ and CD8+ counts may be a valuable independent prognostic tool in predicting the outcome in invasive breast cancer.

Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients

2009 ◽  
Vol 27 (10) ◽  
pp. 1694-1705 ◽  
Author(s):  
Alexandra F. Leary ◽  
Wedad M. Hanna ◽  
Marc J. van de Vijver ◽  
Frederique Penault-Llorca ◽  
Josef Rüschoff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Tissue ◽  
Extracellular Domain ◽  
Prognostic Indicator ◽  
Early Recurrence ◽  
Response To Treatment ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Her 2 ◽  
American Society

The human epidermal receptor-2 (HER-2) is overexpressed or amplified in 15% to 25% of breast cancers. Determination of HER-2 tumor status offers clinically useful information, as it selects patients who may benefit from treatment with trastuzumab, the monoclonal antibody against HER-2. Currently approved methods for HER-2 testing include immunohistochemistry or fluorescent in situ hybridization using tumor tissue. A fragment of HER-2 composed of its extracellular domain (ECD) can also be detected in the serum of some patients with breast cancer. As an easily accessible tumor marker, it could offer additional useful prognostic or predictive information. This review will briefly address the biology of the circulating HER-2 ECD and discuss the evidence to support the role, if any, for measuring HER-2 ECD levels in women with breast cancer. In particular, we focus on the value and limitations of serum ECD in both early and advanced breast cancer in the following clinical contexts: as a marker of HER-2 tumor tissue status; clinical implications of raised levels in women who have a tumor not overexpressing HER-2; as a prognostic indicator and as a predictor of response to treatment; and as a monitoring tool for early recurrence. On the basis of our review of the literature, we conclude that there is currently insufficient evidence to support the use of serum HER-2 ECD in the routine management of individual patients with breast cancer. This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer.

scholarly journals Morphological Heterogeneity of p53 Positive and p53 Negative Nuclei in Breast Cancers Stratified by Clinicopathological Variables

1997 ◽  
Vol 14 (2) ◽  
pp. 111-123
Author(s):  
Katrin Friedrich ◽  
Volker Dimmer ◽  
Gunter Haroske ◽  
Wolfdietrich Meyer ◽  
Franz Theissig ◽  
...  
Keyword(s):  
Tumour Progression ◽  
Tumour Size ◽  
Image Cytometry ◽  
Lymph Node Status ◽  
Nuclear Morphology ◽  
Breast Cancers ◽  
Biological Behaviour ◽  
P53 Expression ◽  
Morphological Heterogeneity ◽  
P53 Immunohistochemistry

The study was aimed to detect differences in nuclear morphology between nuclear populations as well as between tumours with different p53 expression in breast cancers with different clinicopathological features, which also reflect the stage of tumour progression. The p53 immunohistochemistry was performed on paraffin sections from 88 tumour samples. After the cells had been localised by means of an image cytometry workstation and their immunostaining had been categorised visually, the sections were destained and stained by the Feulgen protocol. The nuclei were relocated and measured cytometrically by the workstation.There were significant differences in the nuclear features between tumours as well as between nuclear populations with different p53 expression in the most subgroups. The variability of nuclear shape in tumour groups, classified by the tumour size or the lymph node status, increase with the p53 immunoreactive score, whereas in tumours grouped by the Bloom–Richardson grade features of the chromatin distribution were different between the p53 staining categories.The nuclear subpopulations showed differences in the amount and distribution of chromatin in most subgroups.The results demonstrate the relationship between the nuclear morphology and the p53 expression in different stages of breast cancers. The p53 status is an important factor of the biological behaviour but not the only one.

scholarly journals Loss of CADM1/TSLC1 Expression Is Associated with Poor Clinical Outcome in Patients with Esophageal Squamous Cell Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
De Zeng ◽  
Xiao Wu ◽  
Jin Zheng ◽  
Yixuan Zhuang ◽  
Jiongyu Chen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cox Regression ◽  
Histological Grade ◽  
Disease Free Survival ◽  
Early Recurrence ◽  
Clinicopathological Parameters ◽  
Survival Duration

Aims. We sought to determine the relationship between CADM1/TSLC1 expression and clinicopathological characteristics in patients with esophageal squamous cell carcinoma (ESCC) and the correlation with survival.Materials and Methods. Two hundred and ninety-three ESCC tissues and paired adjacent normal esophageal tissues were immunohistochemically assessed in this study. The association of CADM1/TSLC1 with clinicopathological parameters, as well as disease-free survival (DFS) and overall survival (OS), was determined based on the Kaplan-Meier method and Cox regression models.Results. CADM1/TSLC1 was detected in 236 (80.5%) tumor tissues and 19 (8.0%) paired adjacent normal esophageal tissues. Decreased CADM1/TSLC1 expression was correlated with more advanced histological grade. CADM1/TSLC1 negative tumors were more frequently observed in male cases than in female cases. DFS and OS in the CADM1/TSLC1 negative group were significantly shorter than those in the positive group, particularly in male patients with ESCC.Conclusion. Loss or reduction of CADM1/TSLC1 expression is associated with more advanced histological grade and predicts early recurrence and short survival duration. Thus, loss of CADM1/TSLC1 could be a prognostic factor that can be used to assess the risk of recurrence and survival.

scholarly journals Clinicopathological significance of caspase-3 and Ki-67 expression in canine mammary gland tumours

2016 ◽  
Vol 64 (1) ◽  
pp. 78-89 ◽  
Author(s):  
Helena Rodrigues ◽  
Maria Isabel Carvalho ◽  
Isabel Pires ◽  
Justina Prada ◽  
Felisbina L. Queiroga
Keyword(s):  
Mammary Gland ◽  
Caspase 3 ◽  
Histological Grade ◽  
Tumour Size ◽  
Clinicopathological Parameters ◽  
Malignant Tumours ◽  
Ki 67 ◽  
Regional Lymph Nodes ◽  
Canine Mammary Gland ◽  
Active Caspase

Fifty canine mammary gland tumours (CMGT) (18 benign and 32 malignant) were studied by immunohistochemical detection of active caspase-3 and Ki-67 antigens in order to determine their association with several clinicopathological parameters. The percentage of caspase-3 positive cells was significantly higher in benign tumours as compared to their malignant counterparts (P ≤ 0.001). In the group of malignant tumours there was no significant association between active caspase-3 and the clinicopathological variables considered. The percentage of Ki- 67 positive cells was significantly higher in malignant tumours compared to the benign ones (P ≤ 0.001). In the group of malignant tumours, Ki-67 expression showed a statistically significant association with tumour size (P = 0.025), histological type (P = 0.010), mitotic grade (P ≤ 0.001), nuclear grade (P = 0.025), differentiation grade (P = 0.004), histological grade of malignancy (P = 0.002), and presence of metastases in regional lymph nodes (P = 0.025). Furthermore, this study revealed a negative correlation between the percentages of active caspase-3 and Ki-67 (r = –0.39; P = 0.04). Thus, our results suggest a loss of balance between cell death and cell division in CMGT. Key words: Apoptosis, caspase-3, Ki

scholarly journals Medullary breast carcinoma: a pathologic review and immunohistochemical study using tissue microarray

2021 ◽  
Author(s):  
L Ming ◽  
AR Jara-Lazaro ◽  
PY Cheok ◽  
AA Thike
Keyword(s):  
Lymphovascular Invasion ◽  
Ductal Carcinoma ◽  
Tumour Size ◽  
Growth Factor Receptor ◽  
Disease Free Survival ◽  
Good Prognosis ◽  
Clinicopathological Parameters ◽  
Nodal Stage ◽  
Singapore General Hospital

Introduction: Medullary breast carcinomas (MBCs) are distinguished by circumscribed, high-grade morphology with dense chronic inflammation; they are associated with the basal phenotype but have a relatively good prognosis. Methods: This study aimed to review the clinicopathological features of MBCs diagnosed at the Department of Pathology, Singapore General Hospital and correlate them with immunohistochemical expression of hormonal markers and c-erbB-2, the basal markers p53, cytokeratin (CK) 14, epidermal growth factor receptor (EGFR) and 34BE12, and the follow-up outcome. Results: Using Ridolfi’s criteria for histologic reviews, 62 patients previously diagnosed as having ‘typical MBC’ (n = 26), ‘atypical MBC’ (n = 32) and ‘invasive carcinoma with focal medullary-like features’ (n = 4) were re-classified as follows: ‘typical MBC’ (n = 6; 9.7%), ‘atypical MBC’ (n = 46; 74.2%), and ‘non-medullary infiltrating carcinoma’ (n = 10; 16.1%). Clinicopathological parameters, including ethnicity, age, tumour size and concurrent ductal carcinoma in situ (DCIS), showed no statistically significant correlation with review diagnoses and immunohistochemical findings. Presence of lymphovascular invasion and nodal stage were significantly correlated with recurrence and breast cancer-related deaths, respectively. ER negativity was significantly correlated with triple positivity for basal markers CK14, EGFR and 34BE12, which comprised patients who showed a significantly decreased disease-free survival rate within a 10–15-year follow-up period. Conclusions: Lymphovascular invasion and high nodal stage as well as triple negativity among typical and atypical MBCs that have basal-like phenotype represent a portion of invasive carcinomas with medullary features that may have poor outcomes in this otherwise relatively good prognostic group.

scholarly journals Evaluation and Correlation of Clinicopathological Parameters of Oral Squamous Cell Carcinoma of Gingivobuccal Sulcus with Lymph Node Status - A Retrospective Institutional Analysis in Navi Mumbai

2021 ◽  
Vol 10 (30) ◽  
pp. 2294-2299
Author(s):  
Akash Shegaonkar ◽  
Shilpa Patel ◽  
Niharika Swain ◽  
Jigna Pathak ◽  
Rashmi Hosalkar ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Perineural Invasion ◽  
Tumour Size ◽  
Clinicopathological Parameters ◽  
Lymph Node Status ◽  
Node Status

BACKGROUND Mortality and Morbidity rates in the patients diagnosed with oral cancers remain static despite availability of advanced diagnostic and treatment modalities. For improving the survival status of the patients, a thorough understanding of the factors that predicts the progression of oral cancer is necessary to determine appropriate line of treatment. To do so in practise, critical knowledge regarding the prognostic factors that has high sensitivity holds immense importance. For determination of prognosis in oral cancer patients, clinical and histopathological parameters are widely used for assessment of treatment strategies. The primary objective of this study was to determine the clinical and histopathological prognostic factors in patients of oral squamous cell carcinoma of gingivobuccal sulcus (GBSSCC) treated by surgical intervention (neck dissection). METHODS Histopathological evaluation of archived samples of 60 GBSSCC patients which were treated by surgical intervention (Neck Dissection) in the time period from January 2011 to December 2020. Recurrent cases were excluded. Clinicopathological parameters such as age, sex, habit, tumour site, tumour size, tumour differentiation, depth of invasion, bone invasion, muscle invasion, perineural invasion & extracapsular spread were evaluated & then correlated with lymphnode status. RESULTS Among all the parameters, variables like habit (tobacco use) (P = 0.045), tumour size (P = 0.003), perineural invasion (P = 0.000) emerged as independent prognosticators and significantly correlated to the lymph node status of the patients. CONCLUSIONS This analysis suggests that habit, tumour size, perineural invasion to be consistent, easy to assess and reliable independent prognosticators which are significantly correlated to the lymph node status. To conclude, it is of paramount importance to include the aforementioned prognosticators in histopathological reports for the prediction of clinical outcome and archiving of valued data for future analysis. KEY WORDS Oral Squamous Cell Carcinoma, Gingivobuccal sulcus, Lymph Node Status, ClinicoPathological Prognosticators

scholarly journals RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance

2022 ◽  
Vol 17 (1) ◽  
Author(s):  
Manar Ahmed Abdel-Rahman ◽  
Mena Mahfouz ◽  
Hany Onsy Habashy
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Tumour Size ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Tissue Microarrays ◽  
Positive Lymph Node ◽  
Clinicopathological Parameters ◽  
Breast Cancer Patients ◽  
Ribonucleoside Diphosphate Reductase

Abstract Background Breast cancer is one of the most common types of cancer. Ribonucleotide reductase (RNR) is a heterodimeric tetramer consisting of two Ribonucleoside-diphosphate reductase large subunits (RRM1) and two Ribonucleoside-diphosphate reductase small subunits (RRM2). RRM2 is the building subunit of RNR that is important for synthesis of Deoxynucleoside triphosphate (dNTP) during S phase of cell cycle during DNA replication. RRM2 is associated with poor prognosis in lung and colorectal cancer. In breast cancer, increased RRM2 protein level is strongly correlated with large tumour size, positive lymph node and relapse. In this study, we aimed to study expression of RRM2 in breast cancer and to correlate it with different clinicopathological parameters in Egyptian women. Material and methods This study was performed by investigating RRM2 protein expression in breast cancer and correlating the results with other clinicopathological variables using immunohistochemistry and tissue microarrays. Results About 77% of cases were RRM2 positive. High Ki67 was observed in cases with high RRM2 score. The majority of non-luminal cases expressed RRM2, however this was statistically insignificant. In ER positive group, RRM2 expression was associated with shorter disease free survival with borderline significance. Conclusion RRM2 protein expression can help in evaluating outcome of breast cancer patients and could be a potential therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document